BAYER AG

🇩🇪Germany

Country: 🇩🇪Germany

Ownership: Public

Established: 1863-08-01

Employees: 99.7K

Market Cap: $30.1B

Website: http://www.bayer.com

Clinical Trials

Aflibercept for Retinopathy of Prematurity - Intravitreal Injection Versus Laser Therapy

Phase 3

Completed

Conditions: Retinopathy of Prematurity (ROP)

Interventions: Drug: Eylea (Aflibercept, BAY86-5321)
Procedure: Laser photocoagulation

First Posted Date: 2019-07-01

Last Posted Date: 2022-05-06

Lead Sponsor: Bayer

Target Recruit Count: 113

Registration Number: NCT04004208

Locations: 🇧🇬
UMHAT Sveti Georgi, Plovdiv, Bulgaria
🇧🇬
SHOGAT Prof Dimitar Stamatov, Varna, Bulgaria
🇯🇵
Kurume University Hospital, Kurume, Fukuoka, Japan

and more 61 locations

Study to Investigate Safety, Absorption, Elimination, and Drug Effect of BAY2327949 in Participants With Different Renal Function Status

Phase 1

Completed

Conditions: Pharmacokinetics

Interventions: Drug: BAY2327949

First Posted Date: 2019-07-01

Last Posted Date: 2020-06-11

Lead Sponsor: Bayer

Target Recruit Count: 32

Registration Number: NCT04004195

Locations: 🇩🇪
APEX GmbH, München, Bayern, Germany
🇩🇪
CRS Clinical-Research-Services Kiel GmbH, Kiel, Schleswig-Holstein, Germany

Study to Test the Safety and How Radium-223 Dichloride an Alpha Particle-emitting Radioactive Agent Works in Combination With Pembrolizumab an Immune Checkpoint Inhibitor in Patients With Stage IV Non-small Cell Lung Cancer With Bone Metastases

Phase 1

Terminated

Conditions: Carcinoma, Non-Small-Cell Lung

Interventions: Drug: Radium-223 dichloride (Xofigo, BAY 88-8223)
Drug: Pembrolizumab

First Posted Date: 2019-06-24

Last Posted Date: 2024-10-10

Lead Sponsor: Bayer

Target Recruit Count: 8

Registration Number: NCT03996473

Locations: 🇺🇸
Ccare San Marcos Cancer Center & Urology, San Marcos, California, United States
🇳🇱
Nederlands Kanker Instituut, Amsterdam, Netherlands
🇧🇪
UZ Gent, Gent, Belgium

and more 3 locations

Study to Test the Safety of an Investigational Drug Given Repeatedly to Adult Men With Severe Hemophilia

Phase 1

Withdrawn

Conditions: Hemophilia

Interventions: Drug: BAY1093884

First Posted Date: 2019-06-24

Last Posted Date: 2019-10-22

Lead Sponsor: Bayer

Registration Number: NCT03996486

Study to Gather Information How Often Venous Thromboembolism Occurs in Prostate Cancer Patients in Sweden and How This Condition is Treated With Blood Thinners

Completed

Conditions: Venous Thromboembolism (VTE)

Interventions: Drug: Rivaroxaban (Xarelto, BAY59-7939)
Drug: Apixaban(Eliquis)
Drug: Pradaxa (Dabigatran etexilate)

First Posted Date: 2019-05-29

Last Posted Date: 2021-11-30

Lead Sponsor: Bayer

Target Recruit Count: 97765

Registration Number: NCT03965741

Locations: 🇸🇪
Many Locations, Multiple Locations, Sweden

Study to Investigate Safety, Tolerability, Pharmacokinetics, and Drug-drug Interaction of Multiple Oral Doses of BAY1830839 in Healthy Male Participants

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: BAY1830839
Drug: Placebo
Drug: Midazolam
Drug: Methotrexate

First Posted Date: 2019-05-29

Last Posted Date: 2023-05-09

Lead Sponsor: Bayer

Target Recruit Count: 67

Registration Number: NCT03965728

Locations: 🇩🇪
Charité Research Organisation GmbH, Berlin, Germany

Assessment of Proactive Treatments in Patients With Wet Age-related Macular Degeneration (wAMD) Which Have Never Undergone Treatment of This Particular Disease

Completed

Conditions: Wet Age-related Macular Degeneration

Interventions: Drug: Aflibercept (Eylea, BAY86-5321)

First Posted Date: 2019-05-07

Last Posted Date: 2023-10-27

Lead Sponsor: Bayer

Target Recruit Count: 1563

Registration Number: NCT03939767

Locations: 🇬🇧
Many Locations, Multiple Locations, United Kingdom

Evaluating Effectiveness and Long Term Safety of Damoctocog Alfa Pegol in Patients, Who Have Been Diagnosed With Hemophilia A

Active, not recruiting

Conditions: Hemophilia A

Interventions: Drug: Damoctocog alfa pegol (Jivi, Bay94-9027)

First Posted Date: 2019-04-30

Last Posted Date: 2024-12-17

Lead Sponsor: Bayer

Target Recruit Count: 371

Registration Number: NCT03932201

Locations: 🇺🇸
The Center for Comprehensive Care and Diagnosis of Inherited Blood Disorders, Orange, California, United States
🇺🇸
South Alabama Medical Science Foundation, Mobile, Alabama, United States
🇺🇸
Georgetown University, Washington, District of Columbia, United States

and more 8 locations

Bioequivalence Trial to Prove Equal Blood Concentrations of Two Different Fluconazole Formulations

Phase 1

Completed

Conditions: Pharmacology, Clinical

Interventions: Drug: Fluconazole (BAYT006267) 150 mg capsules
Drug: Fluconazole 150 mg capsules (DiflucanTM)

First Posted Date: 2019-04-29

Last Posted Date: 2019-04-29

Lead Sponsor: Bayer

Target Recruit Count: 26

Registration Number: NCT03929861

A Clinical Study of Anetumab Ravtansine in Adults With Solid Tumors Who Have Been Treated in Previous Bayer-sponsored Anetumab Ravtansine Studies

Phase 2

Terminated

Conditions: Solid Tumors

Interventions: Drug: BAY94-9343 (Anetumab ravtansine)

First Posted Date: 2019-04-24

Last Posted Date: 2023-08-04

Lead Sponsor: Bayer

Target Recruit Count: 9

Registration Number: NCT03926143

Locations: 🇺🇸
Sarah Cannon Cancer Center, Nashville, Tennessee, United States
🇮🇹
ASST Grande Ospedale Metropolitano Niguarda, Milano, Lombardia, Italy
🇺🇸
Mary Crowley Medical Research Center, Dallas, Texas, United States

and more 4 locations

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy